The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study
文献类型：期刊论文
| 作者 | Yu, Xiaoqing2,3; Si, Jinfei4; Wei, Jingwen1; Wang, Yanling2,3; Sun, Yan2,3; Jin, Jianan2,3; Zhang, Xiaoyan5; Ma, Tonghui5; Song, Zhengbo2,3 |
| 刊名 | CANCER MEDICINE
 |
| 出版日期 | 2022-11-15 |
| 关键词 | EGFR-TKIs non-small cell lung cancer (NSCLC) real-world study survival outcome |
| ISSN号 | 2045-7634 |
| DOI | 10.1002/cam4.5413 |
| 通讯作者 | Song, Zhengbo(songzb@zjcc.org.cn) |
| 英文摘要 | Background Few large-scale studies have been published using real-world data related to overall survival (OS) improvements in advanced epidermal growth factor receptor (EGFR)-mutant lung cancer patients; therefore, little is known regarding the characteristics of patients who could benefit most from EGFR-tyrosine kinase inhibitors (TKIs). Our study aimed to assess whether EGFR-TKI treatment confers survival benefits among advanced non-small-cell lung cancer (NSCLC) patients harboring EGFR mutations in the Chinese population. Patients and Methods A total of 6451 advanced NSCLC patients were diagnosed between January 1, 2013 and June 30, 2019 in Zhejiang Cancer Hospital. Ultimately, 2864 patients with a confirmed EGFR mutation genotype were enrolled in our study. OS was measured from the time of diagnosis of advanced NSCLC until death or last follow-up. Results Median follow-up for OS of advanced EGFR-mutant NSCLC patients was 28.33 months in our study. Patients who received EGFR-TKIs demonstrated better survival compared to those without EGFR-TKI treatment (mOS: 29.77 vs. 22.97 months, p < 0.0001). A total of 451 patients switched to third-generation EGFR-TKI treatment and obtained a significantly better survival than those who adopted first-line third-generation EGFR-TKIs or those who did not receive third-generation EGFR-TKIs after disease progression with first- or second-generation EGFR-TKI treatment (mOS: 38.0 vs. 32.5 vs. 28.3 months, p < 0.0001). As for EGFR genotypes, patients with exon 19 deletion showed better OS, followed by those with L858R mutation (32.4 vs. 24.83 months, p = 0.0013). NGS versus PCR testing showed no statistical differences with respect to survival outcomes (mOS: 27.5 vs. 27.47 months, p = 0.6745). Conclusion Advanced EGFR-mutant patients treated with EGFR-TKIs obtained absolute superior survival in the Chinese population. |
| WOS关键词 | TYROSINE KINASE INHIBITORS ; OPEN-LABEL ; PHASE-III ; 1ST-LINE TREATMENT ; ASIAN PATIENTS ; GEFITINIB ; ADENOCARCINOMA ; CHEMOTHERAPY ; MULTICENTER ; AFATINIB |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| WOS记录号 | WOS:000884117300001 |
| 出版者 | WILEY |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/130411]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Song, Zhengbo |
| 作者单位 | 1.Wenzhou Med Univ, Dept Oncol, Clin Med Coll 1, Wenzhou, Zhejiang, Peoples R China 2.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Dept Clin Trial, Canc Hosp, Hangzhou, Peoples R China 3.Chinese Acad Sci, Inst Basic Med & Canc IBMC, Hangzhou, Peoples R China 4.Zhejiang Chinese Med Univ, Dept Oncol, Clin Med Coll 2, Hangzhou, Peoples R China 5.Genetron Hlth Beijing Technol Co Ltd, Dept Translat Med, Beijing, Peoples R China |
| 推荐引用方式 GB/T 7714 | Yu, Xiaoqing,Si, Jinfei,Wei, Jingwen,et al. The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study[J]. CANCER MEDICINE,2022. |
| APA | Yu, Xiaoqing.,Si, Jinfei.,Wei, Jingwen.,Wang, Yanling.,Sun, Yan.,...&Song, Zhengbo.(2022).The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study.CANCER MEDICINE. |
| MLA | Yu, Xiaoqing,et al."The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study".CANCER MEDICINE (2022). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。